{"id":"W2980792813","doi":"10.1016/j.clml.2019.09.275","title":"Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Lenalidomide; Dexamethasone; Internal medicine; Medicine; Ixazomib; Multiple myeloma; Oncology; Hazard ratio; Refractory (planetary science); Progression-free survival; Bortezomib; Overall survival; Carfilzomib; Biology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003012197,0.001004742,0.002600861,0.0005054361,0.000489757,0.001220661,0.00108367,0.001152242,0.001669379],"category_scores_gemma":[0.00145429,0.0002918499,0.002802965,0.0007145631,0.0006456856,0.0011914,0.0005040572,0.001819819,0.0003546581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001337911,"about_ca_system_score_gemma":0.001125801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002191193,"about_ca_topic_score_gemma":0.004415518,"domain_scores_codex":[0.9990332,0.0004709984,0.00005165718,0.0001238781,0.0001162288,0.0002039756],"domain_scores_gemma":[0.9988173,0.0003214678,0.0002853221,0.0001666186,0.00008558029,0.0003237556],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8022203,0.009266136,0.03546708,0.0006095015,0.005806167,0.0004161278,0.0002580285,0.001701681,0.005218768,0.0002376902,0.00258033,0.1362182],"study_design_scores_gemma":[0.4751977,0.1701584,0.325396,0.0002999766,0.01109169,0.001143078,0.0002857419,0.002110691,0.003843991,0.0007613055,0.009545685,0.0001656895],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863784,0.01031018,0.000186236,0.0003459343,0.00007713341,0.0002633299,0.001165941,0.00003953767,0.001233289],"genre_scores_gemma":[0.9932227,0.002575733,0.0003109591,0.0006661504,0.00014431,0.0001782671,0.002063022,0.00001519835,0.0008237619],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003012197,"threshold_uncertainty_score":0.01593018,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03648884867608198,"score_gpt":0.3331541773261949,"score_spread":0.2966653286501129,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}